CN1917868A - 包含l－丝氨酸、l－异亮氨酸、叶酸和痕量元素的用于治疗银屑病的组合物 - Google Patents
包含l－丝氨酸、l－异亮氨酸、叶酸和痕量元素的用于治疗银屑病的组合物 Download PDFInfo
- Publication number
- CN1917868A CN1917868A CNA2005800041621A CN200580004162A CN1917868A CN 1917868 A CN1917868 A CN 1917868A CN A2005800041621 A CNA2005800041621 A CN A2005800041621A CN 200580004162 A CN200580004162 A CN 200580004162A CN 1917868 A CN1917868 A CN 1917868A
- Authority
- CN
- China
- Prior art keywords
- salt
- pharmaceutical composition
- isoleucine
- serine
- folic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 title claims abstract description 35
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 title claims abstract description 30
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 title claims abstract description 29
- 239000011573 trace mineral Substances 0.000 title claims abstract description 21
- 235000013619 trace mineral Nutrition 0.000 title claims abstract description 21
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 title claims abstract description 15
- 229960000304 folic acid Drugs 0.000 title claims abstract description 15
- 239000011724 folic acid Substances 0.000 title claims abstract description 15
- 235000019152 folic acid Nutrition 0.000 title claims abstract description 15
- 201000004681 Psoriasis Diseases 0.000 title abstract description 7
- 239000011651 chromium Substances 0.000 claims abstract description 20
- 239000011669 selenium Substances 0.000 claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 229960000310 isoleucine Drugs 0.000 claims abstract description 16
- 229960001153 serine Drugs 0.000 claims abstract description 16
- 229910052804 chromium Inorganic materials 0.000 claims abstract description 10
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims abstract description 9
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 9
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 9
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 claims abstract description 9
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229930182844 L-isoleucine Natural products 0.000 claims abstract description 6
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims description 19
- 230000001185 psoriatic effect Effects 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 18
- 150000002632 lipids Chemical class 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 12
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 10
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 10
- 230000001537 neural effect Effects 0.000 claims description 9
- 235000005911 diet Nutrition 0.000 claims description 8
- 230000037213 diet Effects 0.000 claims description 8
- 229910052721 tungsten Inorganic materials 0.000 claims description 8
- 239000010937 tungsten Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 150000008575 L-amino acids Chemical class 0.000 claims description 6
- 239000000470 constituent Substances 0.000 claims description 6
- 239000011572 manganese Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052748 manganese Inorganic materials 0.000 claims description 2
- DIMMBYOINZRKMD-UHFFFAOYSA-N vanadium(5+) Chemical class [V+5] DIMMBYOINZRKMD-UHFFFAOYSA-N 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 abstract description 12
- 150000001413 amino acids Chemical class 0.000 abstract description 11
- 229910052718 tin Inorganic materials 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 206010048768 Dermatosis Diseases 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 208000017520 skin disease Diseases 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 235000021152 breakfast Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 230000008859 change Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 230000003319 supportive effect Effects 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了治疗银屑病的生物医学手段。本发明涉及L－丝氨酸(Ser)和L－异亮氨酸(Ile)在制备用于治疗或预防银屑病的药物组合物中的用途。本发明还涉及含有所述氨基酸作为活性成分的药物组合物。优选该组合物还含有至少一种选自铬(Cr)、锡(Sn)、硒(Se)、钒(V)、钨(W)和锌(Zn)的基本痕量元素以及叶酸。
Description
发明领域
本发明涉及天然生物成分在制备用于治疗或预防银屑病的药物组合物中的用途。本发明还涉及含有天然生物成分作为单独的药物活性成分的药物组合物。该组合物对皮肤病具有疗效。
发明背景
银屑病是一种具有多种形态的皮肤病，其特征是在身体的伸肌(extensor)表面形成覆鳞的红斑。银屑病通常为慢性病，其似乎与某种遗传易感性相关。这些患者的治疗复杂而且费用昂贵，但治愈的结果不常见。当病情进展时，还可能牵涉到关节，并导致严重的疼痛，限制了患者的活动。标准的治疗方法近来没有任何丁点的改变，并且通常的疗法仍然是光线治疗，某些药膏和可的松。尚未设计出切实有效的天然疗法。因此，对于改进的治疗银屑病的方法有很大的需求，该方法应当是有效的，简单的，便宜的并且没有有害的副作用。
在当今世界，癌症是导致死亡的主要原因之一，在寻找对这类疾病的治疗方法方面已花费了大量资源。癌症常规地是通过手术、放射或用细胞生长抑制剂来治疗的。可选的治疗方法包括例如被称之为生物免疫疗法的生物和免疫治疗形式的联合(Tallberg，Thomas.Development of aCombined Biological and Immunological Cancer Therapy Modality.Areview of Bio-immunotherapy.J.Austr.Coll.Nutr.& Env.Med.2003：22第3-21页)。在生物免疫疗法中，向癌症患者给予天然生物成分，该天然生物成分由氨基酸和痕量元素的混合物组成，任选地与神经脂类物质(neurogenic lipids)和/或维生素联合。业已针对不同形式的癌症测试了这些成分的不同混合物。这些混合物优选作为食物增补物给予。
本发明基于如下惊人的发现，即在由生物免疫疗法治疗癌症患者期间，若干意外地也患有银屑病的癌症患者的皮肤病变明显消失，或者皮肤疾病的症状明显减轻，尽管他们所接受的癌症治疗并非是针对他们的皮肤病的。这种对银屑病的积极效果似乎与恶性疾病无关，并且与患者所患的任何形式的癌症也不相关。
本发明现在提供了天然生物成分在制备用于治疗或预防银屑病的药物组合物中的用途。
本发明还提供了一种便宜和安全的含有天然生物成分的药物组合物用于治疗或预防银屑病。
通过向需要的个体给药天然生物成分，本发明还提供了一种可选择的治疗或预防银屑病的方法。
发明简述
本发明涉及L-氨基酸丝氨酸(Ser)和异亮氨酸(Ile)在制备用于治疗或预防银屑病的药物组合物中的用途。所述氨基酸以非结合形式(先前被称作单体氨基酸)存在，这意味着该氨基酸并未包含于肽或蛋白质或任何其它大分子或缀合物中，但其可以与组合物的痕量元素离子以复合体的形式存在。
本发明还涉及药物组合物，其含有L-氨基酸丝氨酸(Ser)和异亮氨酸(Ile)，任选地与至少一种选自铬(Cr)、锡(Sn)、硒(Se)、钒(V)和钨(W)的痕量元素联合，和/或连同叶酸一起作为单独的药物活性成分。
本发明还公开了治疗或预防银屑病的方法，这是通过向需要的个体给予药物活性量的L-氨基酸丝氨酸(Ser)和异亮氨酸(Ile)实现的。
本发明一些优选的实施方案阐述于从属权利要求之中。
发明详述
根据对患有银屑病的癌症患者所摄取的天然生物成分的分析，清楚地表明，在他们接受生物免疫疗法中所使用的某些氨基酸与特定的基本痕量元素金属离子一起，对他们的皮肤病产生了积极的临床效果。在这些癌症患者的亲密家庭成员中，那些在其它方面健康，但也经历银屑病发作的人，在摄取同样的天然饮食成分后也能产生有利的临床效果。
因此，研究了那些未患癌症的银屑病患者。在测试的大量病例中详细描述这些活性饮食成分。以食物增补形式给那些患者开具的口服处方是基于含有氨基酸异亮氨酸(Ile)和丝氨酸(Ser)的组合的制剂。所述两种氨基酸以L-氨基酸的形式给予。
除了Ile和Ser之外，组合物优选还含有至少一种选自铬(Cr)、锡(Sn)、硒(Se)、钒(V)、钨(W)和锌(Zn)的基本痕量元素。任选地，痕量元素还包括，举例来说，锰(Mn)。为具有生物活性，痕量元素应为离子形式，为此，实践中它们作为盐的形式给予。优选具有中性味道的盐，应当避免具有浓烈或劣质味道的盐。
优选，治疗或预防银屑病的制剂还含有生理量的叶酸。
根据本发明成功使用的治疗是基于口服给药L-丝氨酸和L-异亮氨酸，任选地和基本痕量元素以及叶酸一起作为活性成分。根据本发明的一个实施方案，组合物基本上由所述的三类成分组成，即氨基酸、痕量元素和维生素。所有这些成分都是天然存在并具有生物活性，这意味着它们参与诸如代谢过程这样的生物学事件。使用含有L-丝氨酸、L-异亮氨酸，Cr盐、Sn盐、Se盐、V盐和W盐，以及叶酸作为单独的药物活性成分的组合物取得了非常好的效果。
所用的组合物含有生物和药物活性量的成分，也就是足以达到期望的健康促进效果的量的成分。正如医师很容易理解的那样，所述的量将根据个体及其健康状况，以及其它因素，例如，体重、年龄、营养、压力和环境因素等，而有所不同。合适的量的实例包括但不限于：L-丝氨酸和L-异亮氨酸各为大约2-10g/天，通常2-5g/天。通常痕量元素的使用量通常为Cr、Sn、Se、V和W的痕量元素离子各为0.5-9mg/天，优选1-3mg/天。Zn可以以大约15mg/天，而Mn可以以大约50mg/天的剂量给予。叶酸以少量已充分确立的生理量使用，如1-2mg/天。
为促进患者淋巴细胞增殖和免疫防御，也可将无朊病毒的神经脂类物质给予用上述组合物治疗的患者。例如，神经脂类物质可自健康小猪的脑中获得。将脑组织煮沸、冷冻并冻干，然后用乙醚-乙基醇像先前描述的那样提取脂类物质从而获得无朊病毒的脂类级分(Tallberg T.等人CancerImmunity.The Effect in Cancer-Immunotherapy of PolymerisedAutologous Tumour Tissue and Supportive Measures.Scand.J.Lab.Invets.1979：39第3-33页)。由芬兰Neurofood Ltd.有限公司购买神经脂类物质并装罐。神经脂类物质的推荐日摄入量相当于大约50-100g脑。
包括氨基酸、痕量元素和维生素的组合物的成分可以分别地或以不同的组合同样地给予。例如，可分别购买它们的散剂，或购买包含所有成分的现成散剂。这种散剂混合物可被事先包装并照此使用，或作为常规食物产品的增补物，例如，用在患者早餐的酸乳酪中。对于消费者来说，很容易将其连同早餐摄入或作为正餐之间的加餐。由于其只包括天然成分，形成活性食物添加剂，因此这种补偿性饮食治疗相对便宜。当然也可将药物组合物加工成颗粒、胶囊或片剂，其可包含药学上可接受的载体或赋形剂。神经脂类产品可以与其它成分同时给予或在不同时间分别给予。优选的方式是将神经脂类产品混入配给的水果中并冷藏摄入。
本发明通过下面的实施例来详细阐述，这些实施例不应当被解释为以任何方式限制其范围。本领域技术人员能够作出具有与文中所述的相同有益效果的改变和修饰。
实施例
以食物增补物的形式向未患癌症的银屑病患者口服给予异亮氨酸和丝氨酸和毫克量的某些生物活性痕量元素盐，其中金属离子以生物学活性形式存在。组合物中还包括了些许毫克的叶酸。每天向这些患者给予这种天然食物增补物。用于治疗银屑病患者的饮食生物调节时间表如下：
联合的支持性饮食措施：
1.口服给药相应的L-氨基酸：丝氨酸(Ser)和异亮氨酸(Ile)(各2-5g/天)，连同膳食一起。
2.作为生物学活性离子口服的基本痕量元素盐，其为些许毫克的剂量水平(1-3mg/天)：铬(CrCl3·6H2O)6mg(＝1.17mg Cr)，锡(SnCl4·SH2O)4mg(＝1.35mg Sn)，硒Na2SeO4·10H2O，6mg(＝1.28mg Se)，钒(Na2VO4·4H2O)，6mg(＝2.5mg V)，钨(Na2WO4·2H2O)，4mg(＝2.3mg W)。某些患者还接受日剂量相当于15mg锌离子的葡萄糖酸锌，而某些患者接受剂量为140mg/天(＝2.5mg Mn)的硫酸锰。
3.小量生理量的叶酸(1-2mg/天)。
4.有些患者额外接受相当于大约50g脑的含有无朊病毒的神经脂类物质的饮食(由芬兰Neurofood Ltd.有限公司购买和罐装)。
5.患者接受事先包装好的含有成分1-3的混合物散剂，并建议将散剂混入到他们的早餐酸乳酪中从而获取日配给量。
6.根据观察到的临床反应调整剂量水平，并与患者体重进行关联。
在几个月的时间内在测试的十多个患者中观察到了积极的治疗效果。局部皮肤斑块变得刺激减轻，并且有些完全消失。关节疼痛减退。在组合物连续用药的情况下，有些病例的效果持续长达20年。积极的临床效果显示出轻微的个体差异，属于这些生物成分的量和相对含量、以及患者体重的差异。在某些病例中，单独的Ile与痕量元素盐联合能产生一定的积极效果，但在其它患者中Ser似乎是必需的辅因子。这种变化可能与银屑病患者的某些遗传特性相关。旨在弥补这种疾病所致的代谢缺陷的这种饮食治疗，与测试的任一志愿者所经历的任何副反应无关。这种食物添加剂能够对银屑病患者发挥持续的减轻效果。
Claims (10)
1.如下物质在制备用于治疗或预防银屑病的药物组合物中的用途：
a)L-氨基酸丝氨酸(Ser)和异亮氨酸(Ile)，
b)痕量元素铬(Cr)、锡(Sn)、硒(Se)、钒(V)和钨(W)，和
c)叶酸。
2.根据权利要求1所述的用途，用于制备的药物组合物还含有锌(Zn)。
3.根据权利要求1或2所述的用途，用于制备的药物组合物还含有锰(Mn)。
4.根据权利要求1所述的用途，用于制备的药物组合物含有：
a)L-丝氨酸和L-异亮氨酸各2-5g，
b)铬(Cr)盐、锡(Sn)盐、硒(Se)盐、钒(V)盐和钨(W)盐各0.5-6mg，和
c)叶酸1-2mg。
5.根据前述任一权利要求所述的用途，用于制备的药物组合物还含有神经脂类物质。
6.根据权利要求1-4任一所述的用途，用于制备散剂形式的药物组合物。
7.根据权利要求5或6所述的用途，用于制备饮食增补组合物。
8.一种药物组合物，其含有如下物质作为单独的药物活性成分：
a)L-氨基酸丝氨酸(Ser)和异亮氨酸(Ile)，
b)痕量元素铬(Cr)、锡(Sn)、硒(Se)、钒(V)和钨(W)，和任选的锌(Zn)，和
c)叶酸。
9.根据权利要求8所述的药物组合物，含有如下物质作为单独的药物活性成分：
a)丝氨酸(Ser)和异亮氨酸(Ile)，
b)铬(Cr)盐、锡(Sn)盐、硒(Se)盐、钒(V)盐、钨(W)盐和锌(Zn)盐，和
c)叶酸。
10.治疗或预防银屑病的方法，其中向需要的个体给予药物活性量的如下物质：
a)L-氨基酸丝氨酸(Ser)和异亮氨酸(Ile)，
b)痕量元素铬(Cr)、锡(Sn)、硒(Se)、钒(V)、钨(W)和任选的锌(Zn)，和
c)叶酸。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20040180 | 2004-02-06 | ||
| FI20040180A FI121915B (fi) | 2004-02-06 | 2004-02-06 | Koostumus psoriasiksen hoitoon |
| PCT/FI2005/000075 WO2005074910A1 (en) | 2004-02-06 | 2005-02-04 | Composition, comprising l-serine, l-isoleucine, folic acid and trace elements, for treating psoriasis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1917868A true CN1917868A (zh) | 2007-02-21 |
| CN1917868B CN1917868B (zh) | 2010-09-01 |
Family
ID=31725662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2005800041621A Expired - Fee Related CN1917868B (zh) | 2004-02-06 | 2005-02-04 | 包含l-丝氨酸、l-异亮氨酸、叶酸和痕量元素的用于治疗银屑病的组合物 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20070258892A1 (zh) |
| EP (1) | EP1718290B1 (zh) |
| JP (1) | JP4919812B2 (zh) |
| CN (1) | CN1917868B (zh) |
| AT (1) | ATE466576T1 (zh) |
| AU (1) | AU2005210181B2 (zh) |
| BR (1) | BRPI0507732A (zh) |
| CA (1) | CA2555328C (zh) |
| DE (1) | DE602005021062D1 (zh) |
| DK (1) | DK1718290T3 (zh) |
| ES (1) | ES2344510T3 (zh) |
| FI (1) | FI121915B (zh) |
| HK (1) | HK1097455A1 (zh) |
| NO (1) | NO20063937L (zh) |
| PL (1) | PL1718290T3 (zh) |
| PT (1) | PT1718290E (zh) |
| RU (1) | RU2372899C2 (zh) |
| WO (1) | WO2005074910A1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102470119A (zh) * | 2009-07-01 | 2012-05-23 | 皮埃尔·法布尔皮肤化妆品公司 | L-丝氨酸作为药物用于预防和/或治疗皮肤炎症应答的用途 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI122450B (fi) * | 2007-12-28 | 2012-01-31 | Neurofood Ab Oy | Koostumus steriilin inflammaation hoitoon |
| CN101947238B (zh) * | 2010-06-24 | 2011-12-21 | 攀枝花兴辰钒钛有限公司 | 治疗癌症的药物组合物及其用途 |
| PT2782566T (pt) | 2011-11-21 | 2021-03-03 | The Inst For Ethnomedicine | L-serina para uso no tratamento de distúrbios neurodegenerativos |
| EP3586849A1 (en) * | 2018-06-29 | 2020-01-01 | Aprofol AG | Folate preparations |
| AU2020334128A1 (en) | 2019-08-21 | 2022-03-10 | Brain Chemistry Labs | Compositions comprising a metal and L-serine, and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL83775A (en) * | 1987-09-04 | 1991-12-15 | Dexter Chemical Corp | Amino acid esters and amides of fumaric acid and pharmaceutical compositions containing them for use in the treatment of psoriasis |
| DE3712986A1 (de) * | 1987-04-16 | 1988-10-27 | Marbert Gmbh | Medizinische zubereitungen auf der grundlage von biertreberextrakt, verfahren zu deren herstellung sowie verwendung von biertreberextrakt zur herstellung von kosmetischen zubereitungen und ein spezieller biertreberextrakt |
| US5326569A (en) * | 1992-12-23 | 1994-07-05 | Abbott Laboratories | Medical foods for the nutritional support of child/adult metabolic diseases |
| CN1080131A (zh) * | 1993-04-28 | 1994-01-05 | 王韵三 | 一种美容保健营养食品和制备方法 |
| US5563132A (en) * | 1994-06-21 | 1996-10-08 | Bodaness; Richard S. | Two-step cancer treatment method |
| US6083293A (en) * | 1997-02-24 | 2000-07-04 | Bath; Virginia L. | Method for enhanced plant protein production and composition for use in the same |
| EP1071414A1 (en) * | 1998-04-24 | 2001-01-31 | Mitokor | Compounds and methods for treating mitochondria-associated diseases |
| GB0019327D0 (en) * | 2000-08-08 | 2000-09-27 | Buchanan Baillie Hamilton Paul | Slimming system |
| US20040086583A1 (en) * | 2002-11-01 | 2004-05-06 | Jensen Claude Jarakae | Anti-angiogenesis effects of morinda citrifolia |
-
2004
- 2004-02-06 FI FI20040180A patent/FI121915B/fi not_active IP Right Cessation
-
2005
- 2005-02-04 PL PL05708155T patent/PL1718290T3/pl unknown
- 2005-02-04 JP JP2006551868A patent/JP4919812B2/ja not_active Expired - Fee Related
- 2005-02-04 CN CN2005800041621A patent/CN1917868B/zh not_active Expired - Fee Related
- 2005-02-04 DE DE602005021062T patent/DE602005021062D1/de active Active
- 2005-02-04 RU RU2006128209/15A patent/RU2372899C2/ru not_active IP Right Cessation
- 2005-02-04 EP EP05708155A patent/EP1718290B1/en active Active
- 2005-02-04 AT AT05708155T patent/ATE466576T1/de active
- 2005-02-04 US US10/588,051 patent/US20070258892A1/en not_active Abandoned
- 2005-02-04 ES ES05708155T patent/ES2344510T3/es active Active
- 2005-02-04 AU AU2005210181A patent/AU2005210181B2/en not_active Ceased
- 2005-02-04 PT PT05708155T patent/PT1718290E/pt unknown
- 2005-02-04 WO PCT/FI2005/000075 patent/WO2005074910A1/en active Application Filing
- 2005-02-04 BR BRPI0507732-0A patent/BRPI0507732A/pt not_active IP Right Cessation
- 2005-02-04 CA CA2555328A patent/CA2555328C/en not_active Expired - Fee Related
- 2005-02-04 DK DK05708155.6T patent/DK1718290T3/da active
-
2006
- 2006-09-04 NO NO20063937A patent/NO20063937L/no not_active Application Discontinuation
-
2007
- 2007-03-29 HK HK07103397.6A patent/HK1097455A1/xx not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102470119A (zh) * | 2009-07-01 | 2012-05-23 | 皮埃尔·法布尔皮肤化妆品公司 | L-丝氨酸作为药物用于预防和/或治疗皮肤炎症应答的用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1718290A1 (en) | 2006-11-08 |
| CA2555328A1 (en) | 2005-08-18 |
| US20070258892A1 (en) | 2007-11-08 |
| PT1718290E (pt) | 2010-07-01 |
| PL1718290T3 (pl) | 2010-10-29 |
| EP1718290B1 (en) | 2010-05-05 |
| ES2344510T3 (es) | 2010-08-30 |
| ATE466576T1 (de) | 2010-05-15 |
| FI20040180A (fi) | 2005-08-07 |
| DE602005021062D1 (de) | 2010-06-17 |
| DK1718290T3 (da) | 2010-08-02 |
| JP4919812B2 (ja) | 2012-04-18 |
| BRPI0507732A (pt) | 2007-07-10 |
| CA2555328C (en) | 2013-03-26 |
| AU2005210181A1 (en) | 2005-08-18 |
| HK1097455A1 (en) | 2007-06-29 |
| RU2006128209A (ru) | 2008-03-20 |
| JP2007520532A (ja) | 2007-07-26 |
| FI121915B (fi) | 2011-06-15 |
| WO2005074910A1 (en) | 2005-08-18 |
| FI20040180A0 (fi) | 2004-02-06 |
| RU2372899C2 (ru) | 2009-11-20 |
| AU2005210181B2 (en) | 2010-05-20 |
| NO20063937L (no) | 2006-09-04 |
| CN1917868B (zh) | 2010-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7069490B2 (ja) | ユウリコマ・ロンギフォリア抽出物並びに免疫系の増強及び／又は刺激におけるその使用 | |
| US20060269617A1 (en) | Supplement compositions and method of use for enhancement of insulin sensitivity | |
| CN113244209A (zh) | 柠檬酸铁在治疗慢性肾脏疾病患者中的应用 | |
| CN1917868B (zh) | 包含l-丝氨酸、l-异亮氨酸、叶酸和痕量元素的用于治疗银屑病的组合物 | |
| DE60214849T2 (de) | Chromium/biotin behandlung von dyslipidämie | |
| DE3348163C2 (zh) | ||
| Hawrysz et al. | Zinc: an undervalued microelement in research and treatment | |
| WO2020221184A1 (zh) | 一种具有降尿酸作用的药物组合物 | |
| JPH04506597A (ja) | 大型中性アミノ酸の食後血漿濃度の低下 | |
| CN102821760B (zh) | 用于治疗神经退行性变疾病或神经血管疾病的新型药物组合物 | |
| CN101917983B (zh) | 用于治疗无菌性炎症的组合物 | |
| RU2741577C2 (ru) | Сублингвальное или буккальное введение dim для лечения заболеваний кожи | |
| RU2201179C2 (ru) | Способ лечения диабетических ретинопатий | |
| US20130059813A1 (en) | Treatment of dermatological conditions | |
| US20210346334A1 (en) | Nutritional chromium compositions and methods of use | |
| WO2010124322A1 (en) | Bicarbonate solution for bioavailable magnesium and uses thereof | |
| DE60318610T2 (de) | Pharmazeutische antidiabetes-zusammensetzung | |
| AT17839U1 (de) | Zusammensetzung gegen Eisenmangel | |
| DE10238677A1 (de) | Vitamin- und Spurenelemente-Mischung für Nierenkranke | |
| US20190083479A1 (en) | Combination medication | |
| WO2003030890A1 (fr) | Activateurs du systeme immunitaire | |
| MATSUO et al. | Pathophysiological Significance of an Oral Zinc Tolerance Test in Patients with Chronic Hepatic Diseases | |
| DE20212933U1 (de) | Vitamin- und Spurenelemente-Mischung für Nierenkranke |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: NERVE FOOD CO., LTD. Free format text: FORMER OWNER: BIOLOGY IMMUNOTHERAPY CO.,INC, HELSINKI SOCIETY Effective date: 20100326 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: HELSINKI, FINLAND TO: ESPOO, FINLAND |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20100326 Address after: Espoo, Finland Applicant after: Oy Neurofood AB Address before: Helsinki Applicant before: Helsingfors Institution Foer B. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100901 Termination date: 20150204 |
|
| EXPY | Termination of patent right or utility model |